Sporothrix brasiliensis is a highly virulent member of the S. schenckii complex, which is responsible for the emergence of the epidemic sporotrichosis in southeastern Brazil over the last two decades. There are no in vivo studies on the sensitivity of S. brasiliensis to the therapeutic regimens used to treat sporotrichosis. Here, we evaluated the efficacy and safety of antifungal treatments against S. brasiliensis using a murine model of disseminated sporotrichosis. In vitro, S. brasiliensis yeasts were sensitive to low concentrations of amphotericin B-deoxycholate (AMB-d) and itraconazole (ITZ), the latter having greater selectivity toward the fungus. The following treatment regimens were tested in vivo: intravenous AMB-d for 7 days post-infection (p.i.), oral ITZ for up to 30 days p.i., and AMB-d followed by ITZ (AMB-d/ITZ). AMB-d and AMB-d/ITZ led to 100% survival of infected mice at the end of the 45-day experimental period. Although all treatments extended mice survival, only AMB-d and AMB-d/ITZ significantly reduced fungal load in all organs, but AMB-d/ITZ led to a more consistent decrease in overall fungal burden. No treatment increased the levels of serum toxicity biomarkers. Taken together, our results indicate that AMB-d/ITZ is the best therapeutic option for controlling disseminated sporotrichosis caused by S. brasiliensis.
Introduction
Sporotrichosis is a subacute or chronic infection caused by thermodimorphic species of the Sporothrix schenckii complex, including S. brasiliensis [1, 2] . This mycosis is becoming a public health problem in the state of Rio de Janeiro, Brazil, due a significant increase in human and animal cases over the last two decades. The leading source of infection in a recent outbreak of sporotrichosis is domestic cats, which can contribute to disease transmission to other animals and to humans by promoting direct inoculation of yeast cells into host tissues [3] . The primary species responsible for feline sporotrichosis in Brazil is S. brasiliensis [4] . Moreover, an epidemiological analyses showed that feline and human sporotrichosis caused by this fungus are spreading from Rio de Janeiro to neighboring Brazilian states, including São Paulo, Minas Gerais, and Paraná. The strains recovered in these states share the genotype found in the Rio de Janeiro outbreak [4] . Importantly, S. brasiliensis was identified in clinical specimens from the most severe cases of sporotrichosis reported in Brazil in recent years [5, 6] .
Sporotrichosis treatment depends on the type of clinical manifestation [7] . For cutaneous or lymphocutaneous disease, oral antifungal agents are the preferred treatment option, and the "gold standard" is one daily 200-mg dose of itraconazole (ITZ). Refractory disease is then treated with two daily oral doses of either ITZ (200 mg) or terbinafine (500 mg) or with three daily doses of a saturated solution of potassium iodide. For patients with life-threatening sporotrichosis (visceral or disseminated), treatment with intravenous amphotericin B (AMB) is required. AMB treatment may be followed by "maintenance" therapy with ITZ; this is the best option for controlling sporotrichosis disseminated in humans [7] . Different animal models, including subcutaneous and intravenous infection in mice, have been used to study the virulence of the two main pathogenic species, S. schenckii sensu stricto and S. brasiliensis; however, these models usually used the mycelial forms and conidia cells to promote the fungal infection [8] [9] [10] [11] [12] [13] . There are no in vivo studies on the sensitivity of the yeast form of S. brasiliensis to the therapeutic regimens used to treat sporotrichosis. Actually, most of the Rio de Janeiro patients are contaminated directly by the yeast form of S. brasiliensis present in cats. Our aim was to evaluate the efficacy and safety of three therapeutic regimens for the treatment of sporotrichosis caused by yeasts from S. brasiliensis using a disseminated murine model of this fungal disease.
Materials and methods

Fungal strain
The highly virulent isolate of feline S. brasiliensis American Type Culture Collection (ATCC) MYA-4823 [9] used in this study was maintained in the mycelial form on potato dextrose agar (PDA; Becton, Dickinson and Company, Sparks, MD, USA) at 28
• C. For conversion to the yeast form, mycelia were subcultured twice in brain-heart infusion broth (Becton, Dickinson and Company, Sparks, MD, USA) at 36 o C under orbital agitation.
Mice
Eight to 10-week-old male BALB/c mice weighing approximately 25 g were maintained in accordance with the National Institutes of Health Animal Care guidelines [14] . All procedures including euthanasia by carbon dioxide poisoning were approved by the Ethics Committee of the Instituto de Biologia Roberto Alcantara Gomes, Universidade do Estado Rio de Janeiro, Brazil (process number CEA/027/2010).
Antifungal drugs
For in vitro assays, ITZ (Sporanox; Janssen-Cilag Pharmaceuticals Inc., Sidney, New South Wales, Australia) and AMB-deoxycholate (AMB-d; Cristalia, São Paulo, Brazil) were diluted in dimethyl sulfoxide. For in vivo assays, ITZ and AMB-d were diluted in sterile phosphate-buffered saline (PBS) or 5% dextrose, respectively.
In vitro antifungal susceptibility assays
In vitro fungal susceptibility to drugs was assayed following Clinical Laboratory Standard Institute broth microdilution methods for mycelia [15] and yeast [16] . Fungal forms were treated with 0. 
In vivo antifungal treatments and survival analysis
We used a modified version of the experimental model of disseminated murine sporotrichosis described by Teixeira et al. [11] . Briefly, mice were inoculated intravenously (through the lateral tail vein) with a suspension of 1 × 10 In addition, to analyze the effectiveness of early ITZ treatment, a group of mice was given ITZ monotherapy (as in "b") starting only 6 hours p.i. (eITZ group), simulating preventive therapy used when patients are scratched by infected cats, the most common form of contamination in Rio de Janeiro. Treated and untreated mice (n = 9 for each group) were monitored daily to evaluate the survival curve for at least 45 days p.i., and other parameters such as animal weight, physical condition, and behavior were also monitored.
Histopathological analysis and fungal load estimation
To analyze treatment effects on different organs, mice from all treatment groups were euthanized 3, 12, 30, or 45 days p.i. with S. brasiliensis (n = 6 mice for each group/time), and their kidneys, liver, lungs, and spleen were removed aseptically and weighed. Liver and kidney samples were fixed in 10% formaldehyde in PBS and prepared for histopathological examination. Paraffin sections of embedded organs were stained using the hematoxylin-eosin stain [18] and analyzed using a single-blind method of semiquantitative estimation of fungal burden and leukocyte reactions, according to the following scale: 0, none; 1, limited; 2, average; 3, high; 4, very high [19] (see also Supplementary Fig. 1 ).
To estimate fungal load in affected organs, 100 µl of a homogenate sample of each organ (kidneys, liver, lungs, and spleen) in PBS was plated onto PDA plates with 50 µg/ml chloramphenicol (Sigma Chemical Co., USA) and incubated at 28
• C for 7 days. After incubation, colonies were counted to determine the colony-forming units per gram of tissue.
Analysis of serum toxicity biomarkers
To estimate treatment toxicity, blood was collected from anesthetized uninfected mice by cardiac puncture 12 or 30 days after the start of antifungal treatment from the following groups: AMB-d group (4 mice); ITZ group (4 mice); AMB-d/ITZ group (4 mice); and control untreated group (15 mice). The following four serum biomarkers of renal and hepatic toxicity were analyzed using kits from Labtest Diagnostica S.A. (São Paulo, Brazil): urea level, creatinine level, aspartate aminotransferase (AST) enzyme activity, and alanine aminotransferase (ALT) enzyme activity.
Statistical Analysis
Statistical analysis was performed using Graph Pad Prism 6.0 (Graph Pad Software Inc., USA), Student t test, and oneway analysis of variance. A P value ≤0.05 was considered statistically significant.
Results
Sporothrix brasiliensis yeasts are susceptible to low concentrations of AMB-d and ITZ in vitro
The antifungal activity of AMB-d and ITZ in vitro was evaluated against the highly virulent S. brasiliensis strain in its mycelia and yeast forms. While both S. brasiliensis fungal forms were equally susceptible to AMB-d (MIC = 0.5 µg/ml), mycelia were much less sensitive to ITZ (MIC = 4 µg/ml) than the yeast form (MIC = 0.5 µg/ml; Table 1 ). The cytotoxic and hemolytic activities of ITZ (against LLC-MK 2 cells and human RBC, respectively) were considerably lower than those observed for AMB-d, resulting in higher SI yeast values for ITZ, which was 8-fold more selective to yeast than to mycelia (Table 1) .
Treatment with AMB-d, alone or followed by ITZ, led to 100% survival of mice infected with S. brasiliensis infections by highly virulent S. brasiliensis yeasts (ATCC MYA-4823). Untreated animals infected with S. brasiliensis reached 100% mortality 26 days p.i. (Fig. 1) . While all therapeutic schemes prolonged the survival of infected mice (P < 0.0001), treatment with AMB-d alone or followed by ITZ showed the highest efficacy, leading to a survival rate of 100% 45 days p.i. In contrast, no mice treated with ITZ alone survived for more than 42 days p.i. (Fig. 1) . All infected animals experienced weight loss and were listless, with shallow breathing and reduced food and water intake; however, the untreated group showed prominent effects as early as 12 days p.i.
AMB-d and AMB-d/ITZ treatments reduced fungal load in affected organs of mice infected with S. brasiliensis
The fungal load in selected organs of mice infected with S. brasiliensis ATCC MYA-4823 was estimated as the number of fungal colonies per gram of tissue (Fig. 2) . Untreated mice displayed a significant increase in fungal load in the liver (40%; P = 0.001) and kidneys (25%; P = 0.02) but not in the spleen and lungs 12 days p.i. compared with pretreatment controls (Fig. 2) . In contrast, both AMB-d alone and AMB-d followed by ITZ led to a significant reduction (30%-40%) in fungal load in all organs analyzed in comparison with the untreated group (Fig. 2) . No statistically significant differences were observed in fungal load between AMB-d and AMB-d/ITZ groups at any of the time points p.i. (12, 30 , or 45 days), except for liver on day 30, where we observed a more reduced fungal load after treatment with AMB-d/ITZ than with AMB-d alone (P < 0.001). ITZ treatment was the least efficient at reducing fungal load (Fig. 2) . At 12 days p.i., the fungal load in all examined organs of mice subjected to ITZ treatment was similar to that observed in untreated mice. However, fungal load had increased 30 days p.i. in the liver and kidneys (Fig. 2) , and, as mentioned previously, no mice in the ITZ group survived 42 days p.i. (Fig. 1) . Interestingly, when ITZ treatment was initiated 6 hours (0.25 days) p.i., 100% mouse survival was achieved up to 42 days p.i. (P < 0.0001; Fig. 3A ). Compared with 6 h p.i., untreated mice had a significant increase in fungal load in the liver only after 12 days p.i. (approximately 30%; P = 0.001; Fig. 3B-E) . This increase was not observed in mice treated with ITZ from 6 h p.i. (Fig. 3B-E) . Indeed, early ITZ treatment promoted a reduction (20%-30%) of fungal load in all organs, except the kidneys, 12 days p.i. when compared with the fungal load observed before treatment ( Fig. 3B-E) . Importantly, early treatment with ITZ was successful in controlling the fungal load in all studied organs up to 45 days p.i. (Fig. 3B-E) .
AMB-d and AMB-d/ITZ promote a sustained reduction in fungal burden and leukocyte reactions in mice infected with S. brasiliensis
According to the histopathological analysis, all treated mice showed a reduction in the fungal burden in the liver and kidneys 12 days p.i. when compared with untreated mice (see Supplementary Materials, Supplementary Fig. 1 could be found in inflamed or abscessed regions in the liver (all antifungal treatments) or kidneys (ITZ or AMB-d/ITZ treatments; data not show). In contrast, untreated animals displayed more drastic liver injury, with areas of necrosis (data not shown). Intense mononuclear phagocyte system reactions (MPSRs) and modest neutrophilic reactions (NRs) were observed in the liver of mice from all treated groups 12 days p.i., while leukocyte reactions in the kidneys were less pronounced (Supplementary Table 1 ). The fungal burden in the liver and kidneys was reduced in all mice surviving 45 days p.i. in the AMB-d, AMBd/ITZ, and eITZ groups (Supplementary Table 1) , and yeast cells could be found inside macrophages or in regions of kidney or liver abscess or necrosis in mice from the AMB-d and AMB-d/ITZ groups (data not shown). NRs of similar intensity were observed in all organs, while MPSRs were more pronounced in some samples, especially in the liver (Supplementary Table 1 ).
Serum toxicity biomarker levels are not affected by AMB-d and ITZ treatments
We measured the serum biomarker levels of liver and renal toxicity in treated but uninfected mice to determine if any of the treatments used elicited appreciable toxic effects. No significant alterations in toxicity biomarkers (urea and creatinine levels and AST and ALT enzymatic activities) were detected after 12 or 30 days of antifungal therapy in any of the treatment groups when compared with untreated animals (see Supplementary Table 2 ).
Discussion
In this study, we evaluated the efficacy and safety of ITZ and AMB-d administration, alone or as sequential treatments, against sporotrichosis caused by a highly virulent S. brasiliensis strain, in an in vivo model of disseminated disease. We are the first to evaluate antifungal therapy with AMB-d and ITZ as maintenance treatment in a murine model of disseminated sporotrichosis caused by yeast cells of S. brasiliensis. We chose the ATCC MYA-4823 isolate of S. brasiliensis for this study because its high virulence had been demonstrated in murine models of sporotrichosis [9, 13] . Although similar MIC values were obtained in vitro for S. brasiliensis yeasts with AMB-d or ITZ (0.5 mg/ml), treatment with AMB-d, alone or followed by ITZ, was the most effective therapy in vivo against disseminated sporotrichosis by S. brasiliensis. These results are similar to those described by Kan and Bennett [20] , on the antifungal treatment of disseminated murine sporotrichosis by S. schenckii isolates. Those authors reported that AMB-d was the most effective treatment against disseminated sporotrichosis, resulting in 100% survival 35 days p.i., with the fewest visible lesions and fungal burden in internal organs [20] . As in our study, Kan and Bennett [20] also observed that ITZ treatment increased mouse survival (90% up to 35 days) but did not fully protect the animals from disseminated disease in the brain, bones, and viscera. Although we observed prolonged survival after ITZ treatment (approximately 80% 35 day p.i.), all animals succumbed by 45 days p.i. (Fig. 1) .
Serum biomarkers of renal and hepatic toxicity (urea and creatinine levels and AST and ALT enzymatic activities) were evaluated in noninfected mice subjected to up to 30 days of antifungal treatments. No alterations were observed in serum of these animals, indicating that all therapy regimens could be used safely, despite the fact that AMB-d had low SI values in vitro, suggestive of toxicity to mammalian cells.
Although both AMB-d and AMB-d/ITZ treatments led to 100% survival of infected mice at the end of the experimental period, we observed less variability in the fungal load among mice treated with AMB-d/ITZ compared with those treated with AMB-d alone (Fig. 2) . Histopathological analysis also showed a reduction in the number of fungal cells in mice treated with AMB-d/ITZ, and inflammatory processes were prominent in this group Table 1 ). Therefore, we describe the overall efficiency of the therapeutic schemes tested on the control of fungal load in mice with disseminated sporotrichosis as follows: AMB-d/ITZ > AMB-d > ITZ. Although ITZ is recommend as the first choice when treating cutaneous and lymphocutaneous forms of sporotrichosis [7] , the results presented here show that this drug does not seem to efficiently treat severe cases caused by S. brasiliensis, confirming recommendations describe by Kauffman et al. 2007 [7] . However, when ITZ treatment was initialized 6 hours p.i. (eITZ), it prolonged mouse survival until 42 days p.i., indicating that earlier ITZ treatment is more efficient than late treatment, especially in cases of S. brasiliensis infection where treatment outcome is dependent on early diagnosis and treatment. These data indicate that ITZ can be considered for treating healthcare professionals and researchers who are accidentally infected by S. brasiliensis or individuals scratched by infected cats, which is the most usual form of contamination by S. brasiliensis in Rio de Janeiro.
We show that AMB-d can be used alone as the drug of choice for the treatment of disseminated S. brasiliensis infection; however, the best option is likely to be AMB-d followed by maintenance treatment with ITZ. These data are in agreement with study results from the limited number of clinical case studies available on the combined use of AMB-d and ITZ [21, 22] . Kohler et al. [21] described a case of a diabetic patient with localized osteoarticular sporotrichosis followed by widespread dissemination of the infection, which was successfully treated with AMB-d followed by oral fluconazole as maintenance treatment. In addition to its use as maintenance therapy, oral ITZ was also successfully combined with intralesional AMB-d in the treatment of refractory feline sporotrichosis [22] .
Conclusions
Our data show that AMB-d followed by ITZ was the best therapeutic regimen for controlling disseminated murine sporotrichosis caused by the emerging S. brasiliensis yeast. These findings are in agreement with the Infectious Diseases Society of America guidelines for treating disseminated sporotrichosis in humans, strongly suggesting that the current first-line therapy used for other species of the S. schenckii complex is also valid for S. brasiliensis. In addition, our work suggests that the murine model of S. brasiliensis sporotrichosis used here is likely to yield clinically meaningful results during in vivo testing of new prospective therapies against S. brasiliensis.
